Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs uses advanced platforms to offer a diverse range of APOL1-targeted recombinant antibodies to customers worldwide. We are committed to providing exceptional, top-tier solutions that are tailored to our customers' specific needs. By constantly pushing the boundaries of research and innovation, we provide unrivaled technical support and service excellence, allowing our customers to achieve their scientific objectives efficiently and effectively.
Apolipoprotein L1 (apoL1) is a minor component of HDL cholesterol, produced in the liver and various other tissues such as the pancreas, kidney, and brain. Each person carries two copies of the APOL1 gene, which are associated with an elevated risk of nondiabetic kidney disease and idiopathic focal segmental glomerulosclerosis (FSGS). Thus, APOL1 is recognized as a "kidney-risk" gene in specific populations, at the same time targeting APOL1 through precise therapeutics is crucial for the effective treatment of related kidney diseases.
APOL1; APOL; APO-L; APOL; APOL-I; Apolipoprotein L; apolipoprotein L, 1; apolipoprotein L1; Apolipoprotein L-I; FSGS4; apolipoprotein L1-B3.
Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Plasma proteins, Potential drug targets, Transporters
Membrane, Secreted (different isoforms)
Cell type enhanced (Glandular and luminal cells, Hepatocytes, Endometrial ciliated cells, Pancreatic endocrine cells)
Low immune cell specificity
Cell line enhanced (EFO-21, HDLM-2, HHSteC, RPTEC TERT1, RT4)
In plasma, interacts with APOA1 and mainly associated with large high density lipoprotein particles.
Here is a selection of top-notch recombinant antibody products offered by Creative Biolabs. Our antibodies are renowned for their outstanding sensitivity, specificity, and purity, guaranteeing the highest quality in product delivery. We provide these products on a global scale to support research and innovation, while also offering excellent technical assistance to our customers.
Cat. No. | Product Name | Target Species | Host Species | Applications |
MOR-0218 | Hi-Affi™ Rabbit Anti-APOL1 Recombinant Antibody (clone DS218AB) | Human | Rabbit IgG | FC, ICC, IP, WB |
MOB-0687MZ | Mouse Anti-APOL1 Recombinant Antibody (clone 2E5) | Human | Mouse IgG1 | ELISA, WB |
VS3-XY86 | Mouse Anti-APOL1 Recombinant Antibody (clone 1D4) | Human | Mouse IgG1 | ELISA, WB |
ZG-0302F | Mouse Anti-ApoL1 Recombinant Antibody (ZG-0302F) | Human | Mouse IgG | ELISA, WB |
Our dedication is to advance research and development by providing unparalleled product quality and exceptional support, empowering the biopharmaceutical community. We ensure that customer satisfaction is our top priority by vigilantly upholding a comprehensive quality management system. This guarantees that our products not only satisfy but exceed industry standards, thereby simplifying the drug development process and providing our customers with superior value.
Fig.1 Anti-APOL1 Recombinant Antibody in WB.
(Cat# ZG-0302F, Creative Biolabs).
Our cutting-edge bioproduction facilities (serum-free mammalian cell expression platform) support comprehensive solutions, from gene synthesis to high-yield bulk production of anti-APOL1 recombinant antibodies. Leveraging our deep expertise and proven methodologies, we deliver cost-effective and rapid turnaround services, tailored to meet the diverse needs of our customers without compromising on quality.
Featured Anti-APOL1 Recombinant Antibody Production Platforms
Fig.2 Milligram-scale anti-APOL1 recombinant antibody production.
Fig.3 Gram-scale anti-APOL1 recombinant antibody production.
Creative Biolabs is dedicated to supporting the research community with an extensive array of cutting-edge recombinant antibodies. We specialize in developing anti-APOL1 antibodies in diverse formats such as full-length, Fab, and scFv. Leveraging our expertise in antibody engineering, we are well-prepared to provide customized solutions that meet the specific needs of your research projects.
Fig.4 Full-Length Anti-APOL1Recombinant Antibody Production and Modalities.
Table 1. APOL1-targeted drug information.
Company | Highest Phase | Classification | Condition |
Immatics (Originator) | Phase III |
Cancer Immunotherapy Cancer Vaccines Peptides Peptide Vaccines |
Cancer, kidney (renal cell carcinoma) Cancer, kidney (renal cell carcinoma, clear cell) |
Maze Therapeutics (Originator) | Phase I | Renal Disorders | |
AstraZeneca Ionis Pharmaceuticals (Originator) |
Phase I |
Antisense Therapy Single-stranded oligodeoxyribonucleotide (DNA) |
Chronic kidney disease Nephropathy Renal and urinary system genetic disorders |
OmniAb (Originator) | Preclinical | Proteinuria | |
Maze Therapeutics (Originator) | Preclinical | Renal Disorders | |
Maze Therapeutics (Originator) | Preclinical | Renal Disorders | |
Ionis Pharmaceuticals (Originator) University of Pennsylvania (Originator) |
Preclinical |
Antisense Therapy Oligonucleotides |
Renal Disorders |
University of Georgia (UGA) (Originator) | Biological Testing |
Bispecific Antibody Fusions Cancer Immunotherapy Fusion Proteins Human Monoclonal Antibodies Polypeptides, from 41 AA Single-Chain V-Domain Antibody Fragment (scFv) |
Cancer |
Ionis Pharmaceuticals (Originator) | Biological Testing |
Antisense Therapy Single-stranded oligodeoxyribonucleotide (DNA) |
Renal Disorders |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
If you would like to gain deeper insights into our anti-APOL1 recombinant antibody offerings, please don't hesitate to reach out to us. We are eager to discuss potential partnerships and provide robust support for your research projects.